PURE Bioscience (PURE) Lifted to “Hold” at ValuEngine
PURE Bioscience (OTCMKTS:PURE) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
Shares of PURE Bioscience (OTCMKTS:PURE) traded down 2.22% on Tuesday, hitting $1.32. 72,019 shares of the company traded hands. The company’s market capitalization is $82.77 million. PURE Bioscience has a 12 month low of $0.75 and a 12 month high of $1.36. The stock’s 50-day moving average price is $1.07 and its 200-day moving average price is $0.96.
PURE Bioscience (OTCMKTS:PURE) last released its quarterly earnings results on Thursday, June 8th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). PURE Bioscience had a negative net margin of 276.96% and a negative return on equity of 125.22%. The firm had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1 million. On average, equities analysts predict that PURE Bioscience will post ($0.10) earnings per share for the current year.
PURE Bioscience Company Profile
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.